September 27, 2016 4:39 PM ET


Company Overview of Bioniz, LLC

Company Overview

Bioniz, LLC, a biopharmaceutical company, focuses on discovering and developing novel peptide therapeutics for the treatment of immune diseases and cancer. The company’s pipeline include BNZ-1, a selective inhibitor of three interleukin cytokines (IL2/IL9/IL15) that are major disease drivers in HTLV-1 Associated Myelopathy (HAM), and in T-cell Leukemias; and IL-15 and IL-21 Inhibitors; and BNZ-3, an early stage asset targeting IL-4, IL-9, and IL-21 cytokines. Bioniz, LLC was founded in 2009 and is based in Irvine, California.

5 Mason Lane

Suite 200

Irvine, CA 92618

United States

Founded in 2009





Key Executives for Bioniz, LLC

Founder, Chief Executive Officer, President and Director
Chief Operating Officer
Age: 45
Vice President of Business Development
Director of Corporate Affairs
Compensation as of Fiscal Year 2016.

Bioniz, LLC Key Developments

Bioniz Therapeutics, Inc. Appoints David Pyott as Chairman of Board of Directors

Bioniz Therapeutics, Inc. announced that it has raised $13 million in its Series A funding. The company also announced that it has appointed Dr. David Pyott as Chairman of the Board of Directors, effective immediately. Dr. Pyott is the past Chairman and Chief Executive Officer of Allergan Inc.

Bioniz Therapeutics, Inc. Appoints Fredrik Wiklund as Chief Operating Officer

Bioniz Therapeutics, Inc. appointed Fredrik Wiklund as its Chief Operating Officer. As a key member of the executive leadership team, Wiklund will be responsible for leading the company's business, operations, strategy, corporate development, finance, commercial planning, investor relations and corporate communications. Wiklund joins Bioniz from Celladon Corporation where he served as Vice President, Corporate Development and Investor Relations.

Bioniz Therapeutics, Inc. Names Kleanthis G. Xanthopoulos as Chairman of its Board of Directors

Bioniz Therapeutics, Inc. announced that is has named Kleanthis G. Xanthopoulos, Ph.D. as Chairman of its Board of Directors. Dr. Xanthopoulos, who joined the Bioniz Board of Directors in 2015. Dr. Xanthopoulos is currently the Executive Chairman of IRRAS AB and a Partner at the Vandel-Group. Dr. Xanthopoulos, who joined the Bioniz Board of Directors in 2015, is a serial entrepreneur and world-renowned luminary in the biotechnology and pharmaceutical industries with significant operational and corporate development expertise. In addition to Dr. Xanthopoulos, Bioniz's board consists of industry legends David Pyott, former Chairman and Chief Executive Officer of Allergan, Inc., Joe Kiani, Founder, Chairman, and CEO of Masimo Corporation, and renowned biotechnology venture capital leader Ilan Zipkin, Ph.D, Senior Investment Director of Takeda Ventures, Inc.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
August 1, 2016
Private Placement
December 17, 2015

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bioniz, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at